

AEOLUS PHARMACEUTICALS, INC.

Form 8-K

October 19, 2005

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington D.C., 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date Of Report (Date Of Earliest Event Reported): 10/19/2005**

**AEOLUS PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Commission File Number: 000-50481**

**Delaware**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**56-1953785**  
(I.R.S. Employer  
Identification No.)

**23811 Inverness Place**  
Laguna Niguel, California 92677  
(Address of Principal Executive Offices, Including Zip Code)

**949-481-9825**  
(Registrant's Telephone Number, Including Area Code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))
-

Edgar Filing: AEOLUS PHARMACEUTICALS, INC. - Form 8-K

Items to be Included in this Report

**Item 8.01. Other Events**

On October 19, 2005, Aeolus Pharmaceuticals, Inc. ("Aeolus") reported the initiation of a multiple dose study of AEOL 10150 in patients with Lou Gehrig's Disease.

A copy of the press release issued by Aeolus on October 19, 2005 announcing this event is attached as Exhibit 99.1 to this Current Report on Form 8-K.

---

**Signature(s)**

Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.

AEOLUS PHARMACEUTICALS, INC.

Date: October 19, 2005.

By: /s/ Michael P. McManus

---

Michael P. McManus  
Chief Accounting Officer, Treasurer and Secretary

**Exhibit Index**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
EX-99.1	Press release dated October 19, 2005